Krystal Biotech, Inc. – NASDAQ:KRYS

Add to watchlist

$143.96

-15.32

-9.62%

Market open

Closed in about 4 hours

-21.58%

month

-21.58%

quarter

+24.16%

year

Market Cap	4.59B
Enterprise value	1.97B

P/E	-15.18
EV/Sales	N/A
EV/EBITDA	-15.14
Price/Sales	N/A
Price/Book	4.08
PEG ratio	0.20
EPS	1.96

Revenue	N/A
EBITDA	-38.43M
Income	57.16M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Krystal Biotech, Inc. (NASDAQ:KRYS): Profit margin
Jun 2023	0	-33.21M
Sep 2023	8.55M	80.74M	943.75%
Dec 2023	42.14M	8.69M	20.63%
Mar 2024	45.25M	932K	2.06%

Krystal Biotech Financials Estimate

Q Y

Krystal Biotech, Inc. (NASDAQ:KRYS): Analyst Estimates
Sep 2025	116.01M	33.89M	29.22%
Oct 2025	133.39M	47.15M	35.35%
Dec 2025	125.03M	37.49M	29.99%
Mar 2026	97.95M	14.74M	15.05%

Analysts Price target
Financials & Ratios estimates

Krystal Biotech, Inc. (NASDAQ:KRYS): Debt to assets
Jun 2023	684026000	30.91M	4.52%
Sep 2023	790350000	34.40M	4.35%
Dec 2023	818355000	39.71M	4.85%
Mar 2024	853296000	54.05M	6.33%

Krystal Biotech, Inc. (NASDAQ:KRYS): Cash Flow
Jun 2023	-34.19M	-15.95M	185.26M
Sep 2023	-21.22M	105.19M	13.38M
Dec 2023	-7.23M	-10.16M	2.61M
Mar 2024	15.88M	-25.98M	10.58M

Krystal Biotech alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Krystal Biotech, Inc. (NASDAQ:KRYS): Employee count
Aug 2023	210
Sep 2023	210
Oct 2023	210
Nov 2023	210
Dec 2023	210
Jan 2024	210
Feb 2024	210
Apr 2024	229
May 2024	229
Jun 2024	229
Jul 2024	229

Krystal Biotech
Hedge Funds Holdings Q1 2023

42.59% -38.98%

of KRYS is owned by hedge funds

101 -51

hedge funds hold KRYS stock

10.85M -10.04M

shares is hold by hedge funds

KRYS hedge funds holdings changes

Krystal Biotech
Insider Trading

Krystal Biotech, Inc. (NASDAQ:KRYS): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	2500
Feb 2024	0	12200
Mar 2024	0	100000
May 2024	0	20000
Jun 2024	0	100000
Sep 2024	0	100000
Dec 2024	0	100000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	13 Dec 2024	KRISHNAN KRISH S director, 10 perc..	Common Stock	727	$170.43	$123,903
Sale	13 Dec 2024	KRISHNAN KRISH S director, 10 perc..	Common Stock	620	$171.63	$106,408
Sale	13 Dec 2024	KRISHNAN SUMA director, 10 perc..	Common Stock	6,302	$163.07	$1,027,661
Sale	13 Dec 2024	KRISHNAN SUMA director, 10 perc..	Common Stock	8,381	$163.91	$1,373,755
Sale	13 Dec 2024	KRISHNAN SUMA director, 10 perc..	Common Stock	4,909	$164.93	$809,646
Sale	13 Dec 2024	KRISHNAN SUMA director, 10 perc..	Common Stock	5,942	$163.04	$968,807
Sale	13 Dec 2024	KRISHNAN KRISH S director, 10 perc..	Common Stock	8,381	$163.91	$1,373,755
Sale	13 Dec 2024	KRISHNAN SUMA director, 10 perc..	Common Stock	1,977	$165.82	$327,834
Sale	13 Dec 2024	KRISHNAN SUMA director, 10 perc..	Common Stock	923	$166.93	$154,074
Sale	13 Dec 2024	KRISHNAN SUMA director, 10 perc..	Common Stock	911	$169.65	$154,549

KRYS insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN Filling date: 17 Nov 2021 Issue date: 1 Sep 2022	17 Nov 2021	1 Sep 2022
Application	Application COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES Filling date: 25 Sep 2019 Issue date: 23 Dec 2021	25 Sep 2019	23 Dec 2021
Application	Application COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES Filling date: 23 Jun 2021 Issue date: 14 Oct 2021	23 Jun 2021	14 Oct 2021
Application	Application COMPOSITIONS AND METHODS FOR ANTIBODY DELIVERY Filling date: 28 Jun 2019 Issue date: 26 Aug 2021	28 Jun 2019	26 Aug 2021
Application	Application COMPOSITIONS AND METHODS FOR GENE DELIVERY TO THE AIRWAYS AND/OR LUNGS Filling date: 18 Dec 2020 Issue date: 24 Jun 2021	18 Dec 2020	24 Jun 2021
Application	Application COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES Filling date: 6 Nov 2020 Issue date: 25 Mar 2021	6 Nov 2020	25 Mar 2021
Application	Application RECOMBINANT NUCLEIC ACIDS ENCODING COSMETIC PROTEIN(S) FOR AESTHETIC APPLICATIONS Filling date: 29 Jun 2020 Issue date: 18 Feb 2021	29 Jun 2020	18 Feb 2021
Grant	Grant Utility: Compositions and methods for delivering CFTR polypeptides Filling date: 7 Feb 2020 Issue date: 10 Nov 2020	7 Feb 2020	10 Nov 2020
Grant	Grant Utility: Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications Filling date: 26 Apr 2019 Issue date: 29 Sep 2020	26 Apr 2019	29 Sep 2020
Application	Application COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES Filling date: 7 Feb 2020 Issue date: 13 Aug 2020	7 Feb 2020	13 Aug 2020

Krystal Biotech
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 6 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 26 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 6 Nov 2023	Q3 2023 Earnings Call Transcript

KRYS earnings call transcripts

Krystal Biotech
Executives

Insider	Age	Compensation
Mr. Krish S. Krishnan (1965) Chairman, Pres & Chief Executive Officer	60	$752,370
Ms. Suma M. Krishnan (1965) Founder, Chief Operating Officer & Director	60	$532,270
Ms. Kathryn A. Romano (1981) Chief Accounting Officer	44	$200,870

Krystal Biotech
Latest News

Friday, 13 December 2024
12:11	KRYS Stock Down on Initial Clinical Updates on KB407 & KB408	zacks.com
Monday, 9 December 2024
16:15	Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa	globenewswire.com
Wednesday, 4 December 2024
12:36	Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?	zacks.com
Wednesday, 27 November 2024
07:00	Krystal Biotech to Present at Upcoming Investor Conferences	globenewswire.com
Wednesday, 6 November 2024
07:00	Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference	globenewswire.com
Tuesday, 5 November 2024
15:01	Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction	zacks.com
Monday, 4 November 2024
15:31	Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript	seekingalpha.com
10:10	Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates	zacks.com
Monday, 28 October 2024
11:05	Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth	zacks.com
07:00	Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024	globenewswire.com
Friday, 18 October 2024
13:00	All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy	zacks.com
Monday, 14 October 2024
16:58	Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On	seekingalpha.com
Friday, 13 September 2024
07:00	Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference	globenewswire.com
Friday, 6 September 2024
07:00	Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Tuesday, 3 September 2024
13:21	Surging Earnings Estimates Signal Upside for Krystal Biotech (KRYS) Stock	zacks.com
Friday, 30 August 2024
14:31	Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?	zacks.com
Friday, 9 August 2024
20:10	Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 8 August 2024
08:26	Best Momentum Stock to Buy for August 8th	zacks.com
07:10	New Strong Buy Stocks for August 8th	zacks.com
Wednesday, 7 August 2024
13:00	Krystal Biotech (KRYS) Upgraded to Buy: What Does It Mean for the Stock?	zacks.com
Monday, 5 August 2024
10:15	Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates	zacks.com
Tuesday, 30 July 2024
23:13	Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)	seekingalpha.com
Monday, 29 July 2024
10:45	5 Biotech Stocks to Bet On Bright Industry Prospects	zacks.com
Friday, 26 July 2024
08:00	Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024	globenewswire.com
Thursday, 18 July 2024
09:51	Krystal Biotech (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why	zacks.com
Thursday, 23 May 2024
13:21	Earnings Estimates Moving Higher for Krystal Biotech (KRYS): Time to Buy?	zacks.com
12:11	Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why	zacks.com
Wednesday, 15 May 2024
08:08	Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB	seekingalpha.com
07:00	Krystal Biotech to Present at the American Thoracic Society 2024 International Conference	GlobeNewsWire
Monday, 6 May 2024
10:11	Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 16 Jun 2025

Is Abeona Therapeutics' Zevaskyn Worth $3.1m Per Treatment, Or Will Krystal Biotech Remain The Market Leader?
Seeking Alpha 21 Apr 2025

Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients
Seeking Alpha 12 Apr 2025

Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher
Seeking Alpha 27 Dec 2024

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy
Seeking Alpha 15 May 2024

Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB
Seeking Alpha 2 May 2024

Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
Seeking Alpha 11 Dec 2023

Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects
Seeking Alpha 22 Sep 2023

Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement
Seeking Alpha 1 Aug 2023

Krystal Biotech: Pioneering Rare Disease Gene Therapies
Seeking Alpha 18 May 2023

Krystal Biotech: A Promising Gene Therapy Innovator

Frequently Asked Questions (FAQ)

What's the price of Krystal Biotech stock today?

One share of Krystal Biotech stock can currently be purchased for approximately $143.96.
When is Krystal Biotech's next earnings date?

Unfortunately, Krystal Biotech's (KRYS) next earnings date is currently unknown.
Does Krystal Biotech pay dividends?

No, Krystal Biotech does not pay dividends.
How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of 4.59B.
What is Krystal Biotech's stock symbol?

Krystal Biotech, Inc. is traded on the NASDAQ under the ticker symbol "KRYS".
What is Krystal Biotech's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Krystal Biotech?

Shares of Krystal Biotech can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Krystal Biotech's key executives?
Krystal Biotech's management team includes the following people:
- Mr. Krish S. Krishnan Chairman, Pres & Chief Executive Officer(age: 60, pay: $752,370)
- Ms. Suma M. Krishnan Founder, Chief Operating Officer & Director(age: 60, pay: $532,270)
- Ms. Kathryn A. Romano Chief Accounting Officer(age: 44, pay: $200,870)
Is Krystal Biotech founder-led company?

Yes, Krystal Biotech is a company led by its founder Ms. Suma M. Krishnan.
How many employees does Krystal Biotech have?

As Jul 2024, Krystal Biotech employs 229 workers.
When Krystal Biotech went public?

Krystal Biotech, Inc. is publicly traded company for more then 8 years since IPO on 20 Sep 2017.
What is Krystal Biotech's official website?

The official website for Krystal Biotech is krystalbio.com.
Where are Krystal Biotech's headquarters?

Krystal Biotech is headquartered at 2100 Wharton Street, Pittsburgh, PA.
How can i contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 Wharton Street, Pittsburgh, PA and company can be reached via phone at +41 25865830.

Krystal Biotech, Inc.

krystalbio.com

Exchange:

NASDAQ

Full time employees:

229

Industry:

Biotechnology

Sector:

Healthcare

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

+41 25865830

2100 Wharton Street
Pittsburgh, PA 15203

CIK: 0001711279
ISIN: US5011471027
CUSIP: 501147102